IRVING - For the fourth consecutive year, McKesson has received approval from the
With this designation for the 2020 program year, McKesson will continue to provide clinicians with the ability to report clinical quality measures directly to CMS through data collected within its industry-leading, oncology-specific electronic health record (EHR), iKnowMedSM.
In addition, six oncology-specific custom QCDR measures identified by physician leaders in The US Oncology Network (The Network) were proposed by McKesson and approved by CMS. The new measures are either outcome or high-priority measures that CMS has recognized as important areas to monitor because they impact patient care and, in many cases, the cost of care: Mutation testing for lung cancer completed prior to start of targeted therapy
Supportive care drug utilization in last 14 days of life
Patient-reported pain improvement
Advance care planning in metastatic cancer patients
Hepatitis B serology testing and prophylactic treatment prior to receiving anti-CD20 targeting drugs
Utilization of PET, PET/CT, or CT scans for breast cancer stage 0, I, or II at any time during the course of evaluation and treatment
These custom measures allow oncology physicians to report on areas they feel are more clinically relevant to the way they practice medicine and may help practices maximize their MIPS score while improving patient outcomes.
'Measures that focus on patient-reported pain improvement and mutation testing in lung cancer are significant. For example, uncontrolled pain is a huge cost driver, and we think documenting results of the pain management plan will improve care. Furthermore, mutation testing in lung cancer leads to the most appropriate and cost-effective therapies, and yet this isn't always done,' said
McKesson's QCDR supports three MIPS practice-reported categories: Quality, Promoting Interoperability, and Improvement Activities. The fourth category, Cost, is calculated based on CMS claims data, so there is nothing additional for practices to report. Through McKesson's QCDR, iKnowMed users gain a wealth of benefits to optimize MIPS performance and value-based care transformation, including: A comprehensive end-to-end solution for data capture through standard workflow, performance monitoring and direct data submission to CMS
Support for 17 MIPS quality measures and six oncology-specific custom QCDR measures
A dashboard providing a high-level visualization of MIPS performance and actionable insights for continuous improvement with the ability to drill down by clinician and into patient-specific data
'We are dedicated to supporting our customers throughout the transition to value-based care,' said
About
Contact:
Tel: 281-825-9927
Email: Claire.Crye@McKesson.com
(C) 2020 Electronic News Publishing, source